| Year |
Citation |
Score |
| 2021 |
Potu H, Kandarpa M, Peterson LF, Durham A, Donato NJ, Talpaz M. Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma. Oncotarget. 12: 160-172. PMID 33613844 DOI: 10.18632/oncotarget.27869 |
0.363 |
|
| 2019 |
Potu H, Kandarpa M, Peterson LF, Donato NJ, Talpaz M. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells. Oncotarget. 10: 5745-5754. PMID 31645897 DOI: 10.18632/oncotarget.27196 |
0.394 |
|
| 2017 |
Pal A, Dziubinski M, Di Magliano MP, Simeone DM, Owens S, Thomas D, Peterson L, Potu H, Talpaz M, Donato NJ. Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. Neoplasia (New York, N.Y.). 20: 152-164. PMID 29248719 DOI: 10.1016/J.Neo.2017.11.007 |
0.399 |
|
| 2017 |
Potu H, Peterson LF, Kandarpa M, Pal A, Sun H, Durham A, Harms PW, Hollenhorst PC, Eskiocak U, Talpaz M, Donato NJ. Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. Nature Communications. 8: 14449. PMID 28198367 DOI: 10.1038/Ncomms14449 |
0.354 |
|
| 2017 |
Peterson LF, Lo MC, Liu Y, Gianolla D, Mitrikeska E, Donato NJ, Johnson CN, Wang S, Mercer J, Talpaz M. Induction of p53 suppresses chronic myeloid leukemia. Leukemia & Lymphoma. 1-14. PMID 28084835 DOI: 10.1080/10428194.2016.1272682 |
0.463 |
|
| 2016 |
Passalacqua KD, Charbonneau ME, Donato NJ, Showalter HD, Sun D, Wen B, He M, Sun H, O'Riordan MX, Wobus CE. Anti-infective activity of 2-cyano-3-acrylamide inhibitors with improved drug-like properties against two intracellular pathogens. Antimicrobial Agents and Chemotherapy. PMID 27139470 DOI: 10.1128/Aac.03021-15 |
0.373 |
|
| 2015 |
Curi DA, Beauchamp EM, Blyth GT, Arslan AD, Donato NJ, Giles FJ, Altman JK, Platanias LC. Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. Oncotarget. 6: 33206-16. PMID 26375673 DOI: 10.18632/Oncotarget.5091 |
0.477 |
|
| 2015 |
Chou DH, Vetere A, Choudhary A, Scully SS, Schenone M, Tang A, Gomez R, Burns SM, Lundh M, Vital T, Comer E, Faloon PW, Dan?ík V, Ciarlo C, Paulk J, ... ... Donato N, et al. Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. Journal of the American Chemical Society. 137: 7929-34. PMID 26042473 DOI: 10.1021/Jacs.5B04284 |
0.479 |
|
| 2015 |
Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, Jakubowiak A, Malek SN, Talpaz M, Donato NJ. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 125: 3588-97. PMID 25814533 DOI: 10.1182/Blood-2014-10-605584 |
0.514 |
|
| 2015 |
Potu H, Peterson LF, Kandarpa M, Fearon E, Talpaz M, Donato NJ. Abstract 3621: Deubiquitination of AXIN1 by USP9X promotes apoptosis in melanoma in response to BRAF or MEK inhibition Cancer Research. 75: 3621-3621. DOI: 10.1158/1538-7445.Am2015-3621 |
0.516 |
|
| 2015 |
Pal A, Magliano MPD, Simeone D, Peterson L, Potu H, Talpaz M, Donato N. Abstract 1748: Usp9x as a novel therapeutic target in human pancreatic cancer Cancer Research. 75: 1748-1748. DOI: 10.1158/1538-7445.Am2015-1748 |
0.404 |
|
| 2015 |
Pricl S, Laurini E, Fermeglia M, Storici P, Giabbai B, Semrau M, March MD, Donato NJ, Quintas-Cardama A. Abstract B61: Bcr-Abl1 V304D mutation in CML: friend or foe? Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B61 |
0.502 |
|
| 2015 |
Pricl S, Laurini E, Fermeglia M, Col VD, Storici P, Giabbai B, Semrau M, March MD, Donato NJ, Quintas-Cardama A. 249 Bcr-Abl1 V304D mutation in CML: Friend or foe? European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)30135-6 |
0.3 |
|
| 2015 |
Peterson LF, Lo M, Lui Y, Gianolla D, Mitrikeska E, Donato NJ, Johnson CN, Wang S, Mercer J, Talpaz M. Targeting p53 in CML Chronic Phase Leukemia Stem Cells Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.04.084 |
0.364 |
|
| 2014 |
Pal A, Donato NJ. Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancer. Breast Cancer Research : Bcr. 16: 461. PMID 25606592 DOI: 10.1186/S13058-014-0461-3 |
0.366 |
|
| 2014 |
Pal A, Young MA, Donato NJ. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Research. 74: 4955-66. PMID 25172841 DOI: 10.1158/0008-5472.Can-14-1211 |
0.374 |
|
| 2014 |
Charbonneau ME, Gonzalez-Hernandez MJ, Showalter HD, Donato NJ, Wobus CE, O'Riordan MX. Small molecule deubiquitinase inhibitors promote macrophage anti-infective capacity. Plos One. 9: e104096. PMID 25093325 DOI: 10.1371/Journal.Pone.0104096 |
0.347 |
|
| 2014 |
Potu H, Peterson LF, Pal A, Verhaegen M, Cao J, Talpaz M, Donato NJ. Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget. 5: 5559-69. PMID 24980819 DOI: 10.18632/Oncotarget.2140 |
0.478 |
|
| 2014 |
Gonzalez-Hernandez MJ, Pal A, Gyan KE, Charbonneau ME, Showalter HD, Donato NJ, O'Riordan M, Wobus CE. Chemical derivatives of a small molecule deubiquitinase inhibitor have antiviral activity against several RNA viruses. Plos One. 9: e94491. PMID 24722666 DOI: 10.1371/Journal.Pone.0094491 |
0.35 |
|
| 2014 |
Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quintás-Cardama A. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proceedings of the National Academy of Sciences of the United States of America. 111: 3550-5. PMID 24550512 DOI: 10.1073/Pnas.1321173111 |
0.447 |
|
| 2014 |
Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, ... Donato NJ, et al. Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). Bioorganic & Medicinal Chemistry. 22: 1450-8. PMID 24457091 DOI: 10.1016/J.Bmc.2013.12.048 |
0.389 |
|
| 2014 |
Potu H, Pal A, Sun H, Peterson L, Talpaz M, Verhaegen M, Cao J, Eskiocak U, Morrison S, Donato NJ. Abstract 4435: Deubiquitinases Usp9x and Usp5 control tumorigenicity and apoptotic responsiveness in malignant melanoma Cancer Research. 74: 4435-4435. DOI: 10.1158/1538-7445.Am2014-4435 |
0.524 |
|
| 2014 |
Pal A, Magliano MPd, Talpaz M, Dziubinski M, Simeone D, Donato NJ. Abstract 4434: Role of Deubiquitinase Usp9x in pancreatic cancers: Tumor promoter or tumor suppressor Cancer Research. 74: 4434-4434. DOI: 10.1158/1538-7445.Am2014-4434 |
0.412 |
|
| 2014 |
Bornmann WG, Peng Z, Maxwell D, Sun D, Bhanu BA, Talpaz M, Donato N, Levitzki A. Abstract 2698: Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I) Cancer Research. 74: 2698-2698. DOI: 10.1158/1538-7445.Am2014-2698 |
0.371 |
|
| 2014 |
Pal A, Luo M, Wicha M, Talpaz M, Donato N. Abstract 2595: Deubiquitinase USP9X inhibition induces apoptosis in metastatic breast cancer cells Cancer Research. 74: 2595-2595. DOI: 10.1158/1538-7445.Am2014-2595 |
0.382 |
|
| 2013 |
Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Talpaz M, Cortes JE, Donato NJ, Quintas-Cardama A. Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia Blood. 122: 853-853. DOI: 10.1182/Blood.V122.21.853.853 |
0.484 |
|
| 2013 |
Potu H, Peterson LF, Verhaegen M, Talpaz M, Donato NJ. Abstract 2323: Mutant B-Raf-mediated activation of deubiquitinases in melanoma defines Usp5 as a potential therapeutic target. Cancer Research. 73: 2323-2323. DOI: 10.1158/1538-7445.Am2013-2323 |
0.504 |
|
| 2013 |
Pricl S, Gibbons DL, Posocco P, Laurini E, Giabbai B, Storici P, Fermeglia M, Sun H, Cortes J, Talpaz M, Donato N, Quintas-Cardama A. Abstract B277: Polymutant BCR-ABL1 proteins during chronic myeloid leukemia therapy: Novel mechanisms of resitance from clinical, in vitro, and in silico evidence. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B277 |
0.461 |
|
| 2012 |
Perry JW, Ahmed M, Chang KO, Donato NJ, Showalter HD, Wobus CE. Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response. Plos Pathogens. 8: e1002783. PMID 22792064 DOI: 10.1371/Journal.Ppat.1002783 |
0.35 |
|
| 2012 |
Peterson LF, Sun H, Liu Y, Kandarpa M, Giannola D, Mercer J, Showalter HD, Jakubowiak A, Talpaz M, Donato NJ. Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth. Blood. 120: 2936-2936. DOI: 10.1182/Blood.V120.21.2936.2936 |
0.5 |
|
| 2011 |
Peng Z, Pal A, Han D, Wang S, Maxwell D, Levitzki A, Talpaz M, Donato NJ, Bornmann W. Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. Bioorganic & Medicinal Chemistry. 19: 7194-204. PMID 22036213 DOI: 10.1016/J.Bmc.2011.09.057 |
0.383 |
|
| 2011 |
Vakana E, Altman JK, Glaser H, Donato NJ, Platanias LC. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood. 118: 6399-402. PMID 22021366 DOI: 10.1182/Blood-2011-01-332783 |
0.507 |
|
| 2011 |
Donato NJ. Imatinib is receptive to a collaboration. Blood. 118: 4009-10. PMID 21998331 DOI: 10.1182/Blood-2011-08-373290 |
0.361 |
|
| 2011 |
Burkholder KM, Perry JW, Wobus CE, Donato NJ, Showalter HD, Kapuria V, O'Riordan MX. A small molecule deubiquitinase inhibitor increases localization of inducible nitric oxide synthase to the macrophage phagosome and enhances bacterial killing. Infection and Immunity. 79: 4850-7. PMID 21911458 DOI: 10.1128/Iai.05456-11 |
0.31 |
|
| 2011 |
Donato NJ. Bcr-Abl adds another twist to cell fate. Blood. 118: 2646-7. PMID 21903901 DOI: 10.1182/Blood-2011-07-366153 |
0.427 |
|
| 2011 |
Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination Cellular Signalling. 23: 2076-2085. PMID 21855629 DOI: 10.1016/J.Cellsig.2011.08.002 |
0.479 |
|
| 2011 |
Kapuria V, Peterson LF, Showalter HD, Kirchhoff PD, Talpaz M, Donato NJ. Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. Biochemical Pharmacology. 82: 341-9. PMID 21621524 DOI: 10.1016/J.Bcp.2011.05.012 |
0.454 |
|
| 2011 |
Albajar M, Gómez-Casares MT, Llorca J, Mauleon I, Vaqué JP, Acosta JC, Bermúdez A, Donato N, Delgado MD, León J. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Molecular Cancer Research : McR. 9: 564-76. PMID 21460180 DOI: 10.1158/1541-7786.Mcr-10-0356 |
0.412 |
|
| 2011 |
Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, Malek SN, Donato NJ, Wang S, Talpaz M. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia. 25: 761-9. PMID 21350558 DOI: 10.1038/Leu.2011.7 |
0.462 |
|
| 2011 |
Donato NJ, Peterson LF. Chronic myeloid leukemia stem cells and developing therapies. Leukemia & Lymphoma. 52: 60-80. PMID 21299460 DOI: 10.3109/10428194.2010.546921 |
0.461 |
|
| 2011 |
Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis Blood. 117: 3151-3162. PMID 21248063 DOI: 10.1182/Blood-2010-03-276477 |
0.56 |
|
| 2011 |
Peterson LF, Sun H, Kapuria V, Kandarpa M, Talpaz M, Jakubowiak AJ, Donato N. Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells Blood. 118: 1835-1835. DOI: 10.1182/Blood.V118.21.1835.1835 |
0.541 |
|
| 2011 |
Peterson LF, Sun H, Young M, Showalter HD, Jakubowiak AJ, Talpaz M, Donato N. Mechanism of Action of a Small Molecule Inhibitor That Targets Usp9x Deubiquitinase Activity in Multiple Myeloma and Mantle Cell Lymphoma Blood. 118: 1415-1415. DOI: 10.1182/Blood.V118.21.1415.1415 |
0.44 |
|
| 2010 |
Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis Cancer Research. 70: 9265-9276. PMID 21045142 DOI: 10.1158/0008-5472.Can-10-1530 |
0.508 |
|
| 2010 |
Lidonnici MR, Audia A, Soliera AR, Prisco M, Ferrari-Amorotti G, Waldron T, Donato N, Zhang Y, Martinez RV, Holyoake TL, Calabretta B. Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells. Cancer Research. 70: 7949-59. PMID 20924107 DOI: 10.1158/0008-5472.Can-10-1667 |
0.416 |
|
| 2010 |
Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proceedings of the National Academy of Sciences of the United States of America. 107: 12469-74. PMID 20616057 DOI: 10.1073/pnas.1005114107 |
0.433 |
|
| 2010 |
Wu J, Meng F, Ying Y, Peng Z, Daniels L, Bornmann WG, Quintás-Cardama A, Roulston D, Talpaz M, Peterson LF, Donato NJ. ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells Leukemia. 24: 869-872. PMID 20111070 DOI: 10.1038/Leu.2009.300 |
0.489 |
|
| 2010 |
Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, Talpaz M. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochemical Pharmacology. 79: 688-97. PMID 19874801 DOI: 10.1016/J.Bcp.2009.10.009 |
0.555 |
|
| 2010 |
Pricl S, Gibbons DL, Posocco P, Laurini E, Fermeglia M, Kantarjian HM, Talpaz M, Cortes J, Young M, Sun H, Peterson LF, Donato N, Quintás-Cardama A. The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML). Blood. 116: 3402-3402. DOI: 10.1182/Blood.V116.21.3402.3402 |
0.477 |
|
| 2010 |
Pricl S, Gibbons DL, Posocco P, Laurini E, Fermaglia M, Kantarjian HM, Talpaz M, Cortes J, Donato N, Quintás-Cardama A. In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1. Blood. 116: 3388-3388. DOI: 10.1182/Blood.V116.21.3388.3388 |
0.302 |
|
| 2010 |
Sun H, Kapuria V, Peterson LF, Giannola D, Malathi K, Talpaz M, Jakubowiak AJ, Donato N. Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma Blood. 116: 3005-3005. DOI: 10.1182/Blood.V116.21.3005.3005 |
0.482 |
|
| 2009 |
Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. The Journal of Clinical Investigation. 119: 1109-23. PMID 19363292 DOI: 10.1172/Jci35660 |
0.549 |
|
| 2009 |
Kapuria V, Peterson LF, Talpaz M, Donato NJ. De-Ubiquitinase Inhibition by WP1130 Induces Formation of Aggresomes, Engages Autophagy and Activates Apoptosis in B-Cell Malignancies. Blood. 114: 3769-3769. DOI: 10.1182/Blood.V114.22.3769.3769 |
0.471 |
|
| 2009 |
Donato NJ, Sun H, Kapuria V, Peterson LF, Bartholomeusz G, Bornmann WG, Talpaz M. WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells. Blood. 114: 3303-3303. DOI: 10.1182/Blood.V114.22.3303.3303 |
0.575 |
|
| 2009 |
Kapuria V, Peterson LF, Bornmann W, Talpaz M, Donato NJ. Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130. Blood. 114: 2907-2907. DOI: 10.1182/Blood.V114.22.2907.2907 |
0.527 |
|
| 2009 |
Peterson LF, Turbiak AJ, Giannola DM, Donato N, Showalter HH, Fearon ER, Talpaz M. Wnt-Pathway Directed Compound Targets Blast Crisis and Chronic Phase CML Leukemia Stem Progenitors. Blood. 114: 2168-2168. DOI: 10.1182/Blood.V114.22.2168.2168 |
0.453 |
|
| 2008 |
Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene. 27: 7055-69. PMID 18794796 DOI: 10.1038/Onc.2008.330 |
0.584 |
|
| 2008 |
Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase Journal of the National Cancer Institute. 100: 926-939. PMID 18577747 DOI: 10.1093/Jnci/Djn188 |
0.526 |
|
| 2008 |
Soliera AR, Lidonnici MR, Ferrari-Amorotti G, Prisco M, Zhang Y, Martinez RV, Donato NJ, Calabretta B. Transcriptional repression of c-Myb and GATA-2 is involved in the biologic effects of C/EBPalpha in p210BCR/ABL-expressing cells. Blood. 112: 1942-50. PMID 18550858 DOI: 10.1182/Blood-2007-09-114975 |
0.35 |
|
| 2008 |
Quintás-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J. Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1T315I and other mutants compared to direct sequencing of the ABL1 kinase domain Leukemia. 22: 885-888. PMID 18305550 DOI: 10.1038/Leu.2008.42 |
0.308 |
|
| 2008 |
Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells Blood. 111: 3821-3829. PMID 18235045 DOI: 10.1182/Blood-2007-08-109330 |
0.538 |
|
| 2008 |
Krijanovski Y, Donato N, Sun H, Meng F, Quintás-Cardama A, Cortés JE, Talpaz M. Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation Clinical Leukemia. 2: 267-271. DOI: 10.3816/Clk.2008.N.037 |
0.381 |
|
| 2008 |
Peterson LF, Sun H, Bornmann W, Peng Z, Maxwell D, Donato N, Talpaz M. Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors Blood. 112: 3212-3212. DOI: 10.1182/Blood.V112.11.3212.3212 |
0.565 |
|
| 2008 |
Lebovic D, Kapuria V, Hari M, Talpaz M, Jakubowiak A, Donato N. WP-1130 Induces Apoptosis in Multiple Myeloma Cells by Inactivation of Jak2 and Syk Tyrosine Kinases Via a Novel Mechanism of Selective Protein Trafficking Blood. 112: 2661-2661. DOI: 10.1182/Blood.V112.11.2661.2661 |
0.55 |
|
| 2008 |
QuintasCardama A, Gibbons DL, Kantarjian HM, Talpaz M, Donato N, Cortes J. Mutational Analysis of Chronic Phase Chronic Myeloid Leukemia (CMLCP) Clones Reveals Heightened BCR-ABL1 Genetic Instability in Patients Failing Sequential Imatinib and Dasatinib Therapy. Blood. 112: 2114-2114. DOI: 10.1182/Blood.V112.11.2114.2114 |
0.351 |
|
| 2008 |
Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Etten RAV, Donato N, Hunter A, Dinsdale D, Tirro E, Vigneri P, et al. Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells. Blood. 112: 1070-1070. DOI: 10.1182/Blood.V112.11.1070.1070 |
0.546 |
|
| 2007 |
Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4233-44. PMID 17634553 DOI: 10.1158/1078-0432.Ccr-06-2981 |
0.536 |
|
| 2007 |
Bartholomeusz G, Talpaz M, Bornmann W, Kong LY, Donato NJ. Degrasyn activates proteasomal-dependent degradation of c-Myc Cancer Research. 67: 3912-3918. PMID 17440106 DOI: 10.1158/0008-5472.Can-06-4464 |
0.344 |
|
| 2007 |
Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood. 109: 3470-8. PMID 17202319 DOI: 10.1182/Blood-2006-02-005579 |
0.541 |
|
| 2007 |
Krijanovski Y, Donato N, Quintas-Cardama A, Cortes J, Talpaz M. Dasatinib Resistance in CML Patients. Identification of Novel BCR-ABL Kinase Domain Mutation. Blood. 110: 1957-1957. DOI: 10.1182/Blood.V110.11.1957.1957 |
0.382 |
|
| 2007 |
Quintás-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J. Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain. Blood. 110: 1952-1952. DOI: 10.1182/Blood.V110.11.1952.1952 |
0.381 |
|
| 2007 |
Quintás-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J. Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy. Blood. 110: 1938-1938. DOI: 10.1182/Blood.V110.11.1938.1938 |
0.362 |
|
| 2007 |
Quintás-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Cortes J, Donato N. Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib. Blood. 110: 1936-1936. DOI: 10.1182/Blood.V110.11.1936.1936 |
0.356 |
|
| 2007 |
Kapuria V, Bartholomeusz G, Kong L, Bornmann W, Peng Z, Pal A, Maxwell D, Talpaz M, Donato N. A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling. Blood. 110: 1556-1556. DOI: 10.1182/Blood.V110.11.1556.1556 |
0.548 |
|
| 2007 |
Donato N, Kapuria V, Sun H, Maxwell D, Bartholomeusz G, Bornmann W, Peng Z, Pal A, Talpaz M. Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation. Blood. 110: 1003-1003. DOI: 10.1182/Blood.V110.11.1003.1003 |
0.553 |
|
| 2006 |
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 354: 2531-41. PMID 16775234 DOI: 10.1056/Nejmoa055229 |
0.416 |
|
| 2006 |
Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni C, Iotti G, Cattelani S, Donato NJ, Calabretta B. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha. Blood. 108: 1353-62. PMID 16670262 DOI: 10.1182/Blood-2006-01-011833 |
0.507 |
|
| 2006 |
Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. The American Journal of Pathology. 168: 962-72. PMID 16507911 DOI: 10.2353/Ajpath.2006.050570 |
0.452 |
|
| 2006 |
Klostergaard J, Leroux ME, Auzenne E, Khodadadian M, Spohn W, Wu JY, Donato NJ. Hyperthermia engages the intrinsic apoptotic pathway by enhancing upstream caspase activation to overcome apoptotic resistance in MCF‐7 breast adenocarcinoma cells Journal of Cellular Biochemistry. 98: 356-369. PMID 16440323 DOI: 10.1002/Jcb.20729 |
0.432 |
|
| 2006 |
Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 107: 2501-6. PMID 16291594 DOI: 10.1182/Blood-2005-07-2966 |
0.489 |
|
| 2006 |
Donato NJ, Wu J, Bornmann W, Talpaz M. Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance. Blood. 108: 4819-4819. DOI: 10.1182/Blood.V108.11.4819.4819 |
0.541 |
|
| 2006 |
Quintas-Cardama A, Cortes J, Kantarjian HM, Talpaz M, Wu J, Meng F, Donato N. A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia. Blood. 108: 4773-4773. DOI: 10.1182/Blood.V108.11.4773.4773 |
0.426 |
|
| 2006 |
Kapuria V, Bartholomeusz G, Bornmann W, Kong LY, Talpaz M, Donato NJ. Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism. Blood. 108: 3423-3423. DOI: 10.1182/Blood.V108.11.3423.3423 |
0.523 |
|
| 2006 |
Pham LV, Tamayo AT, Yoshimura LC, Priebe W, Donato NJ, Talpaz M, Ford RJ. Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in “Classic” and “Blastoid-Variant” Mantle Cell Lymphoma. Blood. 108: 2512-2512. DOI: 10.1182/Blood.V108.11.2512.2512 |
0.496 |
|
| 2006 |
Wu J, Meng F, Talpaz M, Donato NJ. Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells. Blood. 108: 2132-2132. DOI: 10.1182/Blood.V108.11.2132.2132 |
0.558 |
|
| 2006 |
Lesslie D, Parikh N, Shah A, Summy J, Trevino J, Hong D, Donato N, Lee F, Gallick G. Dasatinib (BMS-354825), a dual SRC/ABL tyrosine kinase inhibitor, inhibits tumor formation and prevents malignant ascites in a murine model of peritoneal carcinomatosis Journal of the American College of Surgeons. 203: S87-S88. DOI: 10.1016/J.Jamcollsurg.2006.05.229 |
0.44 |
|
| 2005 |
Gao H, Talpaz M, Lee BN, Donato N, Cortes JE, Kantarjian HM, Reuben JM. BMS-354825 induced complete hematologic remission in chronic phase CML patients without affecting T-cell cytokine production. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6619. PMID 27944263 DOI: 10.1200/Jco.2005.23.16_Suppl.6619 |
0.462 |
|
| 2005 |
Shah N, Sawyers CL, Kantarjian HM, Donato N, Nicoll J, Cortes J, Paquette R, Huang F, Clark E, Talpaz M. Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6521. PMID 27943866 DOI: 10.1200/Jco.2005.23.16_Suppl.6521 |
0.467 |
|
| 2005 |
Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6924-32. PMID 16203784 DOI: 10.1158/1078-0432.Ccr-05-0757 |
0.518 |
|
| 2005 |
Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, Reuben JM. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia. 19: 1905-11. PMID 16151467 DOI: 10.1038/Sj.Leu.2403933 |
0.344 |
|
| 2005 |
Johnson FM, Saigal B, Donato NJ. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Journal of Cellular Physiology. 205: 218-27. PMID 15887238 DOI: 10.1002/Jcp.20383 |
0.489 |
|
| 2005 |
Kong L, Kapuria V, Bartholomeusz G, Talpaz M, Priebe W, Donato NJ. Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma. Blood. 106: 1489-1489. DOI: 10.1182/Blood.V106.11.1489.1489 |
0.474 |
|
| 2005 |
Donato NJ, Wu J, Kong L, Meng F, Lee F, Talpaz M. Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy. Blood. 106: 1087-1087. DOI: 10.1182/Blood.V106.11.1087.1087 |
0.565 |
|
| 2005 |
Trevino JG, Summy JM, Lesslie DP, Lee FY, Donato NJ, Baker CH, Gallick GE. Inhibition of Src expression/activity delays development of metastases in human pancreatic adenocarcinoma Journal of the American College of Surgeons. 201: S80. DOI: 10.1016/J.Jamcollsurg.2005.06.186 |
0.457 |
|
| 2005 |
Gao H, Lee B, Donato NJ, Talpaz M, Reuben JM. Imatinib mesylate (Gleevec, STI-571) suppresses cytokine production by normal T-cells activated through T-cell receptor (TCR) signaling The Journal of Allergy and Clinical Immunology. 115. DOI: 10.1016/J.Jaci.2004.12.893 |
0.332 |
|
| 2004 |
Johnson FM, Yang P, Newman RA, Donato NJ. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. Journal of Experimental Therapeutics & Oncology. 4: 317-25. PMID 15844661 |
0.41 |
|
| 2004 |
Donato NJ, Klostergaard J. Distinct stress and cell destruction pathways are engaged by TNF and ceramide during apoptosis of MCF-7 cells. Experimental Cell Research. 294: 523-33. PMID 15023539 DOI: 10.1016/J.Yexcr.2003.11.021 |
0.451 |
|
| 2004 |
Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M, Shishodin S. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Research. 64: 672-7. PMID 14744784 DOI: 10.1158/0008-5472.Can-03-1484 |
0.539 |
|
| 2004 |
Donato NJ, Wu J, Kong LY, Meng F, Priebe W, Talpaz M. Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia. Blood. 104: 2964-2964. DOI: 10.1182/Blood.V104.11.2964.2964 |
0.555 |
|
| 2004 |
Donato NJ, Wu J, Kong LY, Lee F, Talpaz M. The SRC/ABL Inhibitor BMS-354825 Overcomes Resistance to Imatinib Mesylate in Chronic Myelogenous Leukemia Cells through Multiple Mechanisms. Blood. 104: 1989-1989. DOI: 10.1182/Blood.V104.11.1989.1989 |
0.567 |
|
| 2004 |
Sawyers CL, Shah NP, Kantarjian HM, Donato N, Nicoll J, Bai SA, Huang F, Clark E, DeCillis AP, Talpaz M. Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study. Blood. 104: 1-1. DOI: 10.1182/Blood.V104.11.1.1 |
0.429 |
|
| 2003 |
Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. Journal of Immunology. 171: 3863-3871. PMID 14500688 DOI: 10.4049/Jimmunol.171.7.3863 |
0.5 |
|
| 2003 |
Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 101: 690-8. PMID 12509383 DOI: 10.1182/Blood.V101.2.690 |
0.496 |
|
| 2003 |
Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis Blood. 101: 1053-1062. PMID 12393461 DOI: 10.1182/Blood-2002-05-1320 |
0.468 |
|
| 2001 |
Ling YH, Donato NJ, Perez-Soler R. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines. Cancer Chemotherapy and Pharmacology. 47: 473-480. PMID 11459199 DOI: 10.1007/S002800000239 |
0.442 |
|
| 2001 |
Beresford SA, Davies MA, Gallick GE, Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 21: 313-22. PMID 11429162 DOI: 10.1089/107999001300177501 |
0.666 |
|
| 2001 |
Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood. 97: 2846-53. PMID 11313280 DOI: 10.1182/Blood.V97.9.2846 |
0.481 |
|
| 2001 |
Leroux E, Auzenne E, Weidner D, Wu ZY, Donato NJ, Klostergaard J. Febrile and acute hyperthermia enhance TNF-induced necrosis of murine L929 fibrosarcoma cells via caspase-regulated production of reactive oxygen intermediates. Journal of Cellular Physiology. 187: 256-263. PMID 11268005 DOI: 10.1002/Jcp.1074 |
0.361 |
|
| 2000 |
Mujoo K, Zhang L, Klostergaard J, Donato NJ. Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement. International Journal of Gynecological Cancer. 10: 105-114. PMID 11240661 DOI: 10.1046/J.1525-1438.2000.00018.X |
0.431 |
|
| 1999 |
Doman RK, Perez M, Donato NJ. JNK and p53 stress signaling cascades are altered in MCF-7 cells resistant to tumor necrosis factor-mediated apoptosis. Journal of Interferon and Cytokine Research. 19: 261-269. PMID 10213465 DOI: 10.1089/107999099314199 |
0.44 |
|
| 1999 |
Perez M, Haschke B, Donato NJ. Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor. Oncogene. 18: 967-978. PMID 10023672 DOI: 10.1038/Sj.Onc.1202368 |
0.538 |
|
| 1998 |
Donato NJ, Perez M. Tumor Necrosis Factor-induced Apoptosis Stimulates p53 Accumulation and p21WAF1 Proteolysis in ME-180 Cells Journal of Biological Chemistry. 273: 5067-5072. PMID 9478957 DOI: 10.1074/Jbc.273.9.5067 |
0.452 |
|
| 1996 |
Perez M, Donato NJ. Activation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor correlates with loss of cytotoxic activity. Journal of Interferon and Cytokine Research. 16: 307-314. PMID 9162524 DOI: 10.1089/Jir.1996.16.307 |
0.523 |
|
| 1996 |
Donato NJ, Martin CA, Perez M, Newman RA, Vidal JC, Etcheverry M. Regulation of epidermal growth factor receptor activity by crotoxin, a snake venom phospholipase A2 toxin. A novel growth inhibitory mechanism. Biochemical Pharmacology. 51: 1535-1543. PMID 8630095 DOI: 10.1016/0006-2952(96)00097-4 |
0.38 |
|
| 1996 |
Rosenblum MG, Cheung L, Kim SK, Mujoo K, Donato NJ, Murray JL. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells. Cancer Immunology, Immunotherapy. 42: 115-121. PMID 8620520 DOI: 10.1007/S002620050260 |
0.388 |
|
| 1994 |
Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang HZ, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 730-9. PMID 8151316 DOI: 10.1200/Jco.1994.12.4.730 |
0.346 |
|
| 1993 |
Mujoo K, Donato NJ, Lapushin R, Rosenblum MG, Murray JL. Tumor necrosis factor alpha and gamma-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 13: 166-74. PMID 8471591 DOI: 10.1097/00002371-199304000-00003 |
0.385 |
|
| 1991 |
Donato NJ, Rotbein J, Rosenblum MG. Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cells. Journal of Cellular Biochemistry. 46: 69-77. PMID 1874802 DOI: 10.1002/Jcb.240460111 |
0.406 |
|
| 1989 |
Donato NJ, Ince C, Rosenblum MG, Gallick GE. Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation Journal of Cellular Biochemistry. 41: 139-157. PMID 2482293 DOI: 10.1002/Jcb.240410305 |
0.453 |
|
| Show low-probability matches. |